Liposomes Promote Pulmonary Glucocorticoid Delivery


  1. Suntres, Z.E.
  2. Shek, P.N.
Corporate Authors
Defence and Civil Inst of Environmental Medicine, Downsview ONT (CAN)
The beneficial effects of glucocorticoids in treating pulmonary inflammatory disorders are complicated by systemic adverse effects. Thus, a possible reduction in dosage and dosing frequency would be advnatageous, particularly for patients requiring high doses of the drug. We believe that this can be achieved by developing formulations that increase the retention of glucocorticoids in the lung and a liposome-based drug delivery system may be useful. In the present study, we examined the pulmonary delivery of a liposomal glucocorticoid formulation. Male adult rats were intratracheally instilled with free (3H)dexamethasone (DEX) or (14C) liposome-entrapped (3H) dexamethasone (L-DEX) (800 mu g DEX/kg body weight) and animals were killed at different times within a 72-h treatment period. Pulmonary retention of (3H) DEX in animals instilled with free DEX was found to be approximately 1.5% of the administered dose 4 h post-instillation, with no radioactivity detectable 24 h post-instillation. Liposome encapsulation of the drug altered the pulmonary retention of DEX with about 35% and 8% of radioactivity remaining in the lung at 4 and 24 h post-instillation, respectively. TRUNCATED
Drug delivery;Liposome;Lung;Microencapsulation;Glucocorticoid;Dexamethasone;Antiinflammatory drugs
Report Number
DCIEM-97-P-27 — Reprint
Date of publication
25 Feb 1998
Number of Pages
Reprinted from
Journal of Drug Targeting, vol 6, no 3, 1998, p 175-182
Hardcopy;Document Image stored on Optical Disk

Permanent link

Document 1 of 1

Date modified: